Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

isunakinra

A recombinant protein resembling interleukin-1 (IL-1) receptor antagonist (IL-1Ra), with potential anti-inflammatory, immunomodulatory and antineoplastic activities. Upon administration, isunakinra targets and binds to the IL-1 receptor type 1 (IL-1-R1; IL-1R1; IL1R1), thereby blocking the binding of IL-1 alpha and beta to and activation of its receptor. Blockade of IL-1 activity and IL-1R1-mediated signaling inhibits the release of other pro-inflammatory mediators and may suppress inflammation and immunological responses. This may also abrogate the inflammatory and the immunosuppressive nature of the tumor microenvironment (TME), and may inhibit tumor growth, invasion, metastasis, and angiogenesis. IL-1/IL-1R1 signaling plays a key role in inflammation, which is present in various disease states including certain types of cancer.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search